Sanofi is here to support you and your patients.

Ask us your questions about our products, patient materials or organising a meeting.

T1-Meta Analysis

Download this clinical summary to read about the benefits of Toujeo® in this post-hoc meta-analysis of three Edition 6 month, phase III, randomised trials. The study aimed to explore the risk of hypoglycaemia with Toujeo® vs insulin glargine 100U/mL in a broad pool of people with T1DM including children over the age of 6.


Toujeo® is indicated as treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years. 

Patient Website

Find resources and support for your patients on Toujeo®. Help patients understand the basics of living and staying well with diabetes and how to have a positive start and experience with the medication prescribed to them.

MAT-XU-2205629 (v4.0)
Date of Preparation: September 2023